Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction (GEJ). Pathology must be confirmed at Memorial Sloan Kettering Cancer Center * Tumors that are Her2 positive are eligible * Availability of archived tumor tissue for banking * TanyN+M0 or T3-4NanyM0 tumors * Disease must be clinically limited to the esophagus or GEJ. GEJ tumors must be Siewert Type I-III * No prior chemotherapy * Prior radiation is permitted, provided it does not limit the ability to deliver per-protocol radiation in the opinion of the treating radiation oncologist * Patients must have surgically resectable disease treatable by esophagectomy, as assessed by a thoracic surgeon * mSUV in the primary tumor must be ≥5.0 * Patients must be ≥18 years of age * Eastern Cooperative Oncology Group performance status of 0-1 * Female subjects must either be of non-reproductive potential (i.e. post-menopausal by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause; * OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry * Adequate organ function defined at baseline as: * WBC ≥3,000/ L * ANC ≥1,500/ L * Platelets ≥100,000/ L * Hb ≥9 g/dl * Calculated creatinine clearance \>40 ml/min using Cockcroft-Gault method: Males: Creatinine CL = Weight (kg) x (140 - Age) . (mL/min) 72 x serum creatinine…